The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick action. Early signs like fatig ...

Acute Myeloid leukaemia AML is a fast-growing cancer of the bone marrow that disrupts blood cell production It differs from ...

Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Kura Oncology's ziftomenib shows promise in AML treatment, with FDA Priority Review ahead. Read here for an analysis of KURA ...

A recent study has revealed promising targets for treating childhood acute myeloid leukaemia (AML) driven by NUP98 fusion ...

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that largely affects older adults. Discover the causes, risk factors, how it’s classified, and more information like on ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...